A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs LN 145 (Primary)
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 16 Aug 2017 According to an Iovance Biotherapeutics media release, the first patient has been dosed in this trial. Initial data from this trial are expected in 2018.
- 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
- 26 May 2017 Planned End Date changed from 1 May 2020 to 1 Dec 2023.